Cholesteryl Ester Storage Disease (CESD): clinical, laboratory and histological characteristics in 6 patients
Authors:
S. Mazurová 1; H. Poupětová 2; H. Hůlková 2; L. Ťoukálková 3; Z. Urbanová 1; J. Zeman 1; V. Smolka 4; V. Malinová 1; T. Honzík 1
Authors‘ workplace:
Klinika dětského a dorostového lékařství UK 1. LF a VFN, Prahapřednosta prof. MUDr. J. Zeman, DrSc.
1; Ústav dědičných metabolických poruch UK 1. LF a VFN, Prahapřednosta prof. MUDr. V. Kožich, CSc.
2; Dětské oddělení, Krajská nemocnice T. Bati, a. s., Zlínpřednosta MUDr. P. Pešák
3; Dětská klinika FN a LF Univerzity Palackého, Olomoucpřednosta prof. MUDr. Vladimír Mihál, CSc.
4
Published in:
Čes-slov Pediat 2014; 69 (3): 148-160.
Category:
Case Report
Overview
Introduction:
Cholesteryl Ester Storage Disease (CESD), an inherited deficiency of lysosomal acid lipase (LAL), leads to the accumulation of cholesteryl esters and triglycerides in the lysosomes of many tissues. The disease manifests usually in preschool age with hepatosplenomegaly, hepatopathy and hyperlipidemia with the possibility of progression into hepatic fibrosis and cirrhosis. In adulthood premature atherosclerosis may develop. More severe lethal variant is Wolman disease with zero LAL activity. CESD is panethnic with estimated incidence of 1:40 000.
Aims:
In the Czech Republic between the years 1975–2013 19 patients with CESD and 1 patient with Wolman disease were diagnosed. Here we present the clinical and laboratory data of 6 patients with CESD (age 15.5±4.5 years).
Results:
Calculated prevalence of CESD in the Czech Republic is 1:322 000. The disease in our 6 patients manifested on average in 5.5 years of age with hepatosplenomegaly, hepatopathy (ALT 1.9±0.4, AST 1.6±0.5 μkat/l) and hyperlipidemia (cholesterol 7±1.5 mmol/l, triglycerides 2.8±1.5 mmol/l). In all four patients with representative sample of liver tissue, liver fibrosis was detected, in one patient with progression into cirrhosis. In all patients the diagnosis of CESD was established enzymatically by the significantly decreased activity of LAL in leukocytes (3–19.5% of average control levels) and by typical histological findings in all liver biopsies with microvesicular steatosis with intralysosomal neutral lipid accumulation. Therapy with intravenous application of recombinant enzyme in two-week intervals is now performed as clinical study in all our six patients.
Conclusion:
Prevalence of CESD in the Czech Republic contrasts with the estimated prevalence and indicates significant underdiagnosis. The existence of a new treatment option requires early intervention and centralization of care for patients with CESD.
Key words:
hepatopathy, hepatosplenomegaly, microvesicular liver steatosis, hyperlipidemia, cholesteryl ester storage disease, lysosomal disease
Sources
1. Sloan RH, Fredrickson DS. Enzyme deficiency in cholesteryl ester storage idisease. J Clin Invest 1972 Jul; 51 (7): 1923–1926.
2. Fouchier SW, Defesche JC. Lysosomal acid lipase A and the hypercholesterolaemic phenotype. Curr Opin Lipidol 2013; 24 (4): 332–338.
3. Tadiboyina VT, Liu DM, Miskie BA, et al. Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. Lipids Health Dis 2005; 4: 26.
4. Hoeg JM, Demosky SJ Jr, Pescovitz OH, et al. Cholesteryl ester storage disease and Wolman disease: phenotypic variants of lysosomal acid cholesteryl ester hydrolase deficiency. Am J Hum Genet 1984 Nov; 36 (6): 1190–1203.
5. Cummings MH, Watts GE. Increased hepatic secretion of very-lowdensity lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease. Clin Chem 1995; 41: 1114.
6. Zhang B, Porto AF. Cholesteryl Ester Storage Disease: Protean presentations of lysosomal acid lipase deficiency. Hepatology and Nutrition 2013; 56: 682–685.
7. Hulkova H, Elleder M. Distinctive histopathological features that support a diagnosis of cholesterol ester storage disease in liver biopsy specimens. Histopathology 2012; 60 (7): 1107–1113.
8. Skoog WA, Beck WS. Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood 1956; 11: 436–454.
9. Hartree EF. Determination of protein: A modification of the lowry method that gives a linear photometric response. Analytical Biochemistry 1972; 48: 422–427.
10. Guy GJ, Butterworth J. Acid esterase activity in cultured skin fibroblasts and amniotic fluid cells using 4-methylumbelliferyl palmitate. Clin Chim Acta 1978; 84: 361–371.
11. Elleder M, Poupĕtová H, Ledvinová J, et al. Lysosomal acid lipase deficiency. Overview of Czech patients. Čas Lék čes 1999 Nov 29; 138 (23): 719–724.
12. Smolka V. Nemoc ze střádání esterů cholesterolu – efekt dlouhodobé léčby lovastatinem. Čes a Slov Gastroent a Hepatol 2007; 61 (1): 30–33
13. Bernstein DL, Hulkova H, Bialer MG, et al. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol 2013; 58: 1230–1243.
14. Poupětová H., Ledvinová J., Berná L, et al. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis 2010 Aug; 33 (4): 387–396.
15. Olivarez L, Caggana M, Pass KA, et al. Estimate of the frequency of Wilson’s disease in the US Caucasian population: a mutation analysis approach. Ann Hum Genet 2001; 65: 459–463.
16. Elleder M, Chlumská A, Hyánek J, et al. Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer. J Hepatol 2000; 32: 528–534.
17. Riva S, Spada M, Sciveres M, et al. Hepatocarcinoma in a child with cholesterol ester storage disease. Dig Liver Dis 2008 Sep; 40 (9): 784.
18. vom Dahl S, Mengel E. Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly. Best Pract Res Clin Gastroenterol 2010 Oct; 24 (5): 619–628.
19. Tylki-Szymańska A, Rujner J, Lugowska A, et al. Clinical, biochemical and histological analysis of seven patients with cholesteryl ester storage disease. Acta Paediatr Jpn 1997; 39: 643–646.
20. Elleder M, Ledvinová J, Cieslar P. Subclinical course of cholesterol ester storage disease (CESD) diagnosed in adulthood. Report on two cases with remarks on the nature of the liver storage process. Virchows Arch A Pathol Anat Histopathol 1990; 416: 357–365.
21. Lohse P, Maas S, Lohse P, et al. Compound heterozygosity for a Wolman mutation is frequent among patients with cholesteryl ester storage disease. J Lipid Res 2000 Jan; 41 (1): 23–31.
22. Fasano T, Pisciotta L, Bocchi L, et al. Lysosomal lipase deficiency: molecular characterization of eleven patients with Wolman or cholesteryl ester storage disease. Mol Genet Metab 2012; 105 (3): 450–456.
23. Bowden KL, Bilbey NJ, Bilawchuk LM, et al. Lysosomal acid lipase deficiency impairs regulation of ABCA1 gene and formation of high density lipoproteins in cholesteryl ester storage disease. J Biol Chem 2011 Sep 2; 286 (35): 30624–30635.
24. Guénard F, Houde A, Bouchard L, et al. Association of LIPA gene polymorphisms with obesity-related metabolic complications among severely obese patients. Obesity 2012 Oct; 20 (10): 2075–2082.
25. Balwani M, Breen C, Enns GM, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology 2013; 58 (3): 950–957.
26. Hamilton J, Jones I, Srivastava R, et al. A new method for the measurement of lysosomal acid lipase in dried blood spots using inhibitor Lalistat 2. Clin Chim Acta 2012; 413: 1207–1210.
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2014 Issue 3
Most read in this issue
- Review and proposal for classification of the congenital anomalies of thymus in children
- Hypertension-associated asymptomatic hyperuricaemia in the adolescents
- Diagnostic monitoring and RSV infection epidemiology in Slovakia
- Cholesteryl Ester Storage Disease (CESD): clinical, laboratory and histological characteristics in 6 patients